Straits Times Index
3,385.93 +1.64 (+0.05%) S&P 500
4,136.48 -43.28 (-1.04%) Dow
33,926.01 -127.89 (-0.38%) Nasdaq
12,006.96 -193.84 (-1.59%) BTC-USD
22,806.06 -580.55 (-2.48%) CMC Crypto 200
523.82 -13.04 (-2.43%)
GILD May 2023 75.000 put
| Previous close | 1.2700 |
| Open | 1.2700 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 75.00 |
| Expiry date | 2023-05-19 |
| Day's range | 1.2700 - 1.2700 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Motley Fool
Is Gilead Sciences a Good Stock to Buy Now?
Shares of Gilead Sciences (NASDAQ: GILD) marched higher on Thursday, Feb. 2 in response to a fourth-quarter earnings report that exceeded expectations. A day later, the U.S. Food and Drug Administration (FDA) agreed to dramatically increase the addressable patient population for an important cancer drug called Trodelvy. Gilead Sciences splashed out with a $21 billion acquisition of Immunomedics in 2020 for access to Trodelvy.
- Zacks
Gilead (GILD) Q4 Earnings & Sales Top on Biktarvy & Oncology
Gilead's (GILD) Q4 earnings and sales beat on strong HIV and oncology business. The guidance for 2023 was also ahead of expectations.
- Business Wire
U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer
FOSTER CITY, Calif., February 03, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) has approved Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in
